FDA Approved Ozempic/Wegovy/Semaglutide
• Physician weight loss program
• Lose up to 2-4 pounds per week
• Reduces appetite and cravings
• Safe and effective
• One weekly injection
W H A T I S S E M A G L U T I D E ?
Semaglutide is a revolutionary GLP-1 receptor agonist that was originally developed for patients with Type 2 diabetes, but when providers and pharmaceutical developers noticed how much weight their patients were losing, they began to study semaglutide exclusively for weight loss. A series of clinical trials known as the STEP clinical trials demonstrated that almost 90% of patients lost 5% or more of their body weight. There is no other weight loss drug on the market that compares. In June of 2022, the FDA approved semaglutide for weight loss.
H O W D O E S S E M A G L U T I D E W O R K ?
Semaglutide acts like GLP-1 (a gut hormone) to:
- Increase insulin production
- Decrease glucagon synthesis
- Delay gastric emptying
- Suppress hunger. It signals your brain that you are full so you can lose weight without feeling like you are depriving yourself.
W H A T A R E P O T E N T I A L. S I D E E F F E C T S ?
- Commonly reported GI side effects – nausea, vomiting, diarrhea, constipation, abdominal pain
- Site reactions
W H O I S. N O T A C A N D I D A T E F O R S E M A G L U T I D E A T
P H Y S I C I A N S R E H A B I L I T A T I O N ?
- < 18 years old
- Type 1 diabetes mellitus
- Hypersensitivity to semaglutide or any components of this medication Personal or family
- history of medullary thyroid carcinoma
- History of multiple endocrine neoplasia syndrome
- History of pancreatitis
- End stage renal disease (on dialysis)
- Family history of thyroid cancers
- Type 2 diabetic patients that are on insulin or a sulfonylurea
- Patients with diabetic retinopathy
- Patients with that are on several antihypertensive medications
W H O I S A C A N D I D A T E ?
- Everyone else*
*Health history, medications, and body weight information will be carefully reviewed by a licensed provider to determine each candidate’s eligibility.